The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC
The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC
Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
Research highlights in gastrointestinal tumours
Updates from ASCO 2024 in gastrointestinal tumours
Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC
Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer
Administering systemic chemotherapy improves survival for patients with resectable CRCLM
Immunotherapy significantly increases the number of patients free from bowel cancer
ASCO 2024: Highlights and analysis
Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC
Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures